Artwork

Content provided by HemaSphere Journal. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by HemaSphere Journal or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ppacc.player.fm/legal.
Player FM - Podcast App
Go offline with the Player FM app!

Episode 2.6 - High 5hmC predicts worse OS

25:15
 
Share
 

Manage episode 459815866 series 3484302
Content provided by HemaSphere Journal. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by HemaSphere Journal or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ppacc.player.fm/legal.

In this episode of the HemaSphere podcast, host Charles de Bock discusses the latest research on myelodysplastic syndrome (MDS) with Dr Francesca Tiso and Dr Florentien in 't Hout from Radboud University Medical Center, co-authors of a recent paper published in HemaSphere. The conversation covers the clinical presentation of MDS, treatment options, and the significance of genetic mutations. Delve into their study on the prognostic value of hydroxymethylation levels in patients treated with azacitidine, highlighting the challenges of risk stratification and patient recruitment. They also discuss future research directions and the comparative efficacy of azacitidine and decitabine.

“High 5hmC predicts worse OS” is on our website and all major podcast platforms (Spotify, Apple Podcast, and more) and YouTube.

Listen and enjoy casual, insightful discussions about #hematology research.

You can find the referenced article, in full and open access, here on the HemaSphere website.

  continue reading

21 episodes

Artwork
iconShare
 
Manage episode 459815866 series 3484302
Content provided by HemaSphere Journal. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by HemaSphere Journal or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ppacc.player.fm/legal.

In this episode of the HemaSphere podcast, host Charles de Bock discusses the latest research on myelodysplastic syndrome (MDS) with Dr Francesca Tiso and Dr Florentien in 't Hout from Radboud University Medical Center, co-authors of a recent paper published in HemaSphere. The conversation covers the clinical presentation of MDS, treatment options, and the significance of genetic mutations. Delve into their study on the prognostic value of hydroxymethylation levels in patients treated with azacitidine, highlighting the challenges of risk stratification and patient recruitment. They also discuss future research directions and the comparative efficacy of azacitidine and decitabine.

“High 5hmC predicts worse OS” is on our website and all major podcast platforms (Spotify, Apple Podcast, and more) and YouTube.

Listen and enjoy casual, insightful discussions about #hematology research.

You can find the referenced article, in full and open access, here on the HemaSphere website.

  continue reading

21 episodes

All episodes

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Quick Reference Guide

Copyright 2025 | Privacy Policy | Terms of Service | | Copyright
Listen to this show while you explore
Play